Brofaromine

Jump to: navigation, search
Brofaromine
File:Brofaromine.svg
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Protein binding98%
Elimination half-life9 to 14 hours
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H16BrNO2
Molar mass310.186 g/mol

Brofaromine is a reversible inhibitor of monoamine oxidase A primarily useful in the treat ment of depression and anxiety. It is not commercially available and is not being actively researched, possibly due to a lack of financial interest.[1]

Pharmacology

Brofaromine is a reversible inhibitor of monoamine oxidase A (RIMA, a type of monoamine oxidase inhibitor (MAOI)) and acts on epinephrine (adrenaline), norepinephrine (noradrenaline), serotonin, and dopamine. Unlike standard MAOIs, possible side effects do not include cardiovascular complications (hypertension) with encephalopathy, liver toxicity or hyperthermia.

References

  1. Lotufo-Neto F, Trivedi M, Thase ME (1999). "Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression". Neuropsychopharmacology. 20 (3): 226–47. doi:10.1016/S0893-133X(98)00075-X. PMID 10063483. Free full text

nl:Brofaromine


Linked-in.jpg